Amed Co (7575) Fair Value & Analysis
Healthcare · TW · Market cap 300M TWD
Fair value as of: Jul 23, 2026
From 17 valuation models · updated 18 days ago
Share price −44.0% over the past month.
Below-average quality, screening 103% undervalued on our models.
What matters now
- The price is below even our cautious bear case (14.94 TWD). The market is more pessimistic than our downside scenario.
- Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (14.94 TWD to 27.75 TWD) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
49‑month range 10.00 TWD – 69.76 TWD · fair‑value band 14.94 TWD – 27.75 TWD · the 10.50 TWD price screens below the 21.34 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Amed Co (7575) currently trades at 10.50 TWD, while our model-based Fair Value estimate is 21.34 TWD, implying the stock looks roughly 103.2% undervalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Net debt stands at 454M TWD. The stock trades on a trailing P/E of 16.1. Fundamentals as of Jul 23, 2026
Our scenario range runs from 14.94 TWD (bear case) to 27.75 TWD (bull case); at 10.50 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 103%, 7575 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Dividend Discount (31.97 TWD) versus Economic Profit (7.34 TWD). Highest evidence: Residual Income (76).
Notify me when 7575 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 9
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name.
Full company description
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-acting pain reliever injections under the Naldebain brand name. In addition, it offers pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. The company was founded in 2008 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amed Co reported revenue of 822M TWD in FY2025 versus 559M TWD in FY2021, a compound +10.1%/yr. Reported net income was 35.8M TWD in FY2025, compounding −7.9%/yr from FY2021.
Watch 7575: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Amed Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amed Co (7575) overvalued or undervalued?
What is the fair value of 7575?
What is the quality score of 7575?
What is the net profit margin of 7575?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Amed Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.